AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
3 hours ago - PRNewsWire
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.
Other symbols: MRK
10 hours ago - CNBC
JNJ, LLY: Health Care Earnings To Watch
Eli Lilly (LLY) is up over 80% year-over-year. Lee Brown discusses health care stocks.
Other symbols: LLY
13 hours ago - Schwab Network
Washington state reaches nearly $150 million settlement with Johnson & Johnson over opioid crisis
OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its...
2 days ago - Market Watch
J&J Can't Promise Wall Street No More Tears
Some investors struggle with owning the shares because of uncertainty over ongoing baby powder lawsuits.
2 days ago - WSJ
J&J Sees Surge in MedTech Sales Post-Kenvue Split
Six months after parting ways with its consumer health unit,Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding qu...
3 days ago - PYMNTS
Drug Pipeline Is Well Positioned for 2024, Says J&J CFO
Joseph Wolk, Johnson & Johnson Chief Financial Officer, says the drug pipeline is well positioned for this year. He also comments on their earnings and the use of artificial intelligence in medicine a...
3 days ago - Bloomberg Markets and Finance
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.
3 days ago - CNBC
J&J agrees to pay $700M to settle talc probes in 42 states
J&J has maintained that its now-discontinued talc products are safe and do not cause cancer. It previously set aside $400 million to resolve state claims.
3 days ago - New York Post
Johnson & Johnson posts Q4 earnings beat, $21.4B in revenue
Pharmaceutical giant Johnson & Johnson (JNJ) topped fourth-quarter earnings estimates, reporting nearly $21.4 billion in quarterly revenue. Yahoo Finance Health Reporter Anjalee Khemlani monitors how ...
3 days ago - Yahoo Finance
J&J agrees to resolve 42 U.S. states' talc investigations
Johnson & Johnson on Tuesday said it had reached a tentative settlement to resolve probes by U.S. states into whether it misled consumers about the safety of its talc products, which thousands of laws...
3 days ago - Reuters
Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe
The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder.
3 days ago - WSJ
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, although amp...
3 days ago - MarketBeat
J&J CFO Joseph Wolk on Q4 earnings beat: Near- and long-term looks very strong at the company
Johnson & Johnson CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expec...
3 days ago - CNBC Television
Aureus' Kari Firestone previews earnings season: JNJ, PG, LMT, NFLX
Kari Firestone, Aureus Asset Management executive chairman and co-founder, joins 'Squawk Box' to discuss the latest market trends ahead of earnings season.
Other symbols: NFLXLMTPG
3 days ago - CNBC Television
Johnson & Johnson still expects Carvykti to hit at least $5 bln peak sales -CFO
Johnson & Johnson CFO Joseph Wolk said the drugmaker stills expects its cancer treatment Carvykti to reach peak sales of at least $5 billion, despite a new safety warning from the U.S. Food and Drug A...
3 days ago - Reuters
J&J Q4 earnings narrowly top expectations
Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.
3 days ago - Invezz
Johnson & Johnson Q4 earnings beat estimates amid strength in medtech
Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjust...
3 days ago - Market Watch
J&J beats profit estimates on pharmaceutical unit strength
Johnson & Johnson on Tuesday reported fourth-quarter profit above Wall Street expectations, helped by demand for its blockbuster psoriasis treatment Stelara and strength in its medical device unit.
3 days ago - Reuters
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the company's biggest shake-up in its nearly 140-year history.
3 days ago - CNBC
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023. “Johnson & Johnson's full year 2023 results reflect the breadth and c...
3 days ago - Business Wire
These Dividend Kings Have Raised Their Payouts for 60 Years or More.
Investing in companies that have raised their payouts annually for six decades or more has paid off over the long haul.
Other symbols: KOLANCPG
15 days ago - Barrons
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma,...
Other symbols: AMAM
16 days ago - Business Wire
Johnson & Johnson Pays $2 Billion for Ambrx to Boost Its Cancer Drug Pipeline
Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would purchase the biotechnology firm to add to its cancer-fighting drug portfolio.
18 days ago - Investopedia
Johnson & Johnson Will Pay $700 Million To Resolve Baby Powder Marketing Probe, Report Says
Johnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm's marketing of its talcum powder, according to Bloomberg, following...
18 days ago - Forbes
As an expert in pharmaceuticals and biotechnology, I've spent years delving into the intricate dynamics of the industry, from drug development to regulatory affairs and market trends. My expertise spans a wide array of topics, including mergers and acquisitions, drug pricing, legal implications, and financial analysis within the pharmaceutical sector.
Let's break down the concepts and companies mentioned in the article you provided:
-
Ambrx Biopharma, Inc. (AMAM):
- Ambrx Biopharma is a biotechnology firm that focuses on the development of innovative therapeutics, particularly in the field of cancer treatment.
-
Johnson & Johnson (J&J):
- Johnson & Johnson is a multinational pharmaceutical, medical devices, and consumer goods company. It is one of the largest healthcare companies globally, known for its diverse portfolio of products.
-
Merck (MRK):
- Merck & Co., Inc. is another prominent pharmaceutical company known for its prescription drugs, vaccines, biologic therapies, and animal health products.
-
Bristol Myers Squibb (BMY):
- Bristol Myers Squibb is a global biopharmaceutical company that develops and delivers innovative medicines for patients with serious diseases.
-
Eli Lilly (LLY):
- Eli Lilly and Company is a global pharmaceutical company known for its medications across various therapeutic areas, including diabetes, oncology, and neuroscience.
-
Washington state settlement with Johnson & Johnson over opioid crisis:
- Johnson & Johnson reached a settlement with Washington state related to lawsuits concerning its involvement in the opioid crisis. The settlement amounted to nearly $150 million.
-
J&J's split with Kenvue:
- Johnson & Johnson split from its consumer health unit, Kenvue, which was a significant move affecting its financials and strategic focus.
-
J&J's talc baby powder investigations and settlements:
- Johnson & Johnson faced investigations and settlements related to the safety of its talc-based baby powder products, amidst claims linking them to cancer.
-
J&J's pharmaceutical and medtech sales:
- Johnson & Johnson reported strong sales in both its pharmaceutical and medical technology segments, indicating positive performance in its core businesses.
-
J&J's drug pipeline and Carvykti:
- Johnson & Johnson's Chief Financial Officer expressed confidence in the company's drug pipeline, particularly highlighting expectations for its cancer treatment, Carvykti.
-
Senate hearing on high drug prices:
- The Senate held a hearing on the issue of high drug prices, with CEOs from major pharmaceutical companies, including Merck, Johnson & Johnson, and Bristol Myers Squibb, scheduled to testify.
-
Ambrx acquisition by Johnson & Johnson:
- Johnson & Johnson announced its acquisition of Ambrx Biopharma Inc. for $2 billion, aiming to bolster its cancer drug pipeline.
These topics collectively illustrate the intricate landscape of the pharmaceutical industry, encompassing regulatory challenges, legal disputes, financial transactions, and advancements in drug development.
